Heartening News.

M2 PRESSWIRE-22 December 2005-Emerging Stock Report: Heartening News(C)1994-2005 M2 COMMUNICATIONS LTD

RDATE:22122005

Today ten million people are at risk of Sudden Cardiac Death. Of that huge group over 400,000 will die from SCD this year, many of them without any warning.

The Emerging Stock Report initiates coverage on Cambridge Heart, Inc. (OTCBB-CAMH) up 31% today on news that the company has announced the publication of a proposed national coverage decision by The Centers for Medicare and Medicaid Services.

Following the analysis CMS states, "Extensive clinical evidence has revealed that patients with symptoms of life threatening arrhythmias who test positive for T-Wave Alternans are at significant risk for subsequent development of sudden cardiac events including death, while those who test negative are at minimal risk." Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. The Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the only diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts.

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible.

Preventing Sudden Cardiac Death requires identifying those patients at the greatest risk. Cambridge Heart's innovative Heartwave System is the first FDA-approved, noninvasive diagnostic tool that can detect the life-threatening heart rhythm disturbances that can lead to SCD. The clinically proven Microvolt T-Wave Alternans Test can be performed quickly and safely in a doctor's office with accuracy comparable to the electrophysiology (EP) test.

Ian Birrell

The Emerging Stock Report profiles emerging growth companies and brings them to the attention of the investment community ahead of the market providing concise analysis and resources required in determining when a stock appears poised for growth.

Get a Complimentary Subscription at www.emergingstockreport.com Subscribers have access to investment research reports, tools for tracking and analyzing, current news, detailed company profiles and ESR "E-Alert" Services. ESR produces comprehensive, timely and dependable research available on the Internet.

Safe Harbor

All material herein was prepared by the Emerging Stock Report (ESR) www.emergingstockreport.com based upon information believed to be reliable. The information contained herein is not guaranteed by ESR to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. ESR is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. ESR may receive compensation in cash or shares from independent third parties or from the companies mentioned.

ESR' s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. ESR will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ESR undertakes no obligation to update such statements

CONTACT: e-mail: ian@emergingstockreport.com

((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data prepared by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).